Compare VTSI & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | IBIO |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 52.8M |
| IPO Year | 1999 | 2009 |
| Metric | VTSI | IBIO |
|---|---|---|
| Price | $2.65 | $0.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $6.25 | $5.69 |
| AVG Volume (30 Days) | 26.9K | ★ 828.6K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,971.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.54 | $0.69 |
| 52 Week High | $6.08 | $3.82 |
| Indicator | VTSI | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 34.69 |
| Support Level | $2.54 | $0.73 |
| Resistance Level | $2.82 | $1.52 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 32.14 | 35.51 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.